Indeed, several reports support the superior efficacy of combining inhibitors of the PI3K/AKT/mTOR and AR signaling pathways in reducing tumor growth, both in vitro and in vivo preclinical studies [124,131,150,154]. The gene discussed is PIK3CA; the disease is neoplasm.